Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.45 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA4 | P22748 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18840376 | 1.00 | FOLH1 (0.45) | FOLH1LTA4HCA1CA2CA4 | |
| SCHEMBL19798112 | 0.93 | FOLH1 (0.41) | FOLH1LTA4HCA1CA2CA4 | |
| SCHEMBL9032439 | 0.88 | FOLH1 (0.45) | FOLH1S1PR1DPP4 | |
| SCHEMBL3000798 | 0.88 | FOLH1 (0.44) | FOLH1DPP4 | |
| SCHEMBL6858941 | 0.88 | FOLH1 (0.44) | FOLH1DPP4 | |
| SCHEMBL5864632 | 0.87 | FOLH1 (0.45) | FOLH1CA1CA2CA4CA9 | |
| SCHEMBL19605901 | 0.87 | FOLH1 (0.45) | FOLH1MEN1KMT2AS1PR1DPP4 | |
| SCHEMBL1996255 | 0.87 | FOLH1 (0.45) | FOLH1CA1CA2CA4CA9 | |
| SCHEMBL1079200 | 0.87 | FOLH1 (0.45) | FOLH1CA1CA2CA4CA9 | |
| SCHEMBL16645337 | 0.87 | L3MBTL1 (0.45) | FOLH1MEN1KMT2AS1PR1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066156-A1 | Targeted Radiotherapy Chelates for In Situ Immune Modulated Cancer Vaccination | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2024-02-29 | — | — | US | disclosed |
| US-20230398239-A1 | Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-12-14 | — | — | US | disclosed |
| US-20230310610-A1 | Long-Lived Gadolinium Based Tumor Targeted Imaging and Therapy Agents | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-10-05 | — | — | US | disclosed |
| US-20180126012-A1 | Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2018-05-10 | — | — | US | disclosed |
| US-20180021461-A1 | TARGETED RADIOTHERAPY CHELATES FOR IN SITU IMMUNE MODULATED CANCER VACCINATION | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2018-01-25 | — | — | US | disclosed |
| US-20170128572-A1 | LONG-LIVED GADOLINIUM BASED TUMOR TARGETED IMAGING AND THERAPY AGENTS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021461-A1 | TARGETED RADIOTHERAPY CHELATES FOR IN SITU IMMUNE MODULATED CANCER VACCINATION | CD47, STING1, ARG1 | FOLH1 431/4885LTA4H 1959/4885CA1 189/4885 |
| US-20170128572-A1 | LONG-LIVED GADOLINIUM BASED TUMOR TARGETED IMAGING AND THERAPY AGENTS | H1-3, H1-2, H1-4 | FOLH1 522/4885LTA4H 2067/4885CA1 403/4885 |
| US-20230398239-A1 | Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies | CD274, CD47, PDCD1 | FOLH1 2412/4885LTA4H 3388/4885CA1 1356/4885 |
| US-20240066156-A1 | Targeted Radiotherapy Chelates for In Situ Immune Modulated Cancer Vaccination | CD47, STING1, ARG1 | FOLH1 431/4885LTA4H 1959/4885CA1 189/4885 |
| US-20230310610-A1 | Long-Lived Gadolinium Based Tumor Targeted Imaging and Therapy Agents | H1-2, H1-3, H1-0 | FOLH1 437/4885LTA4H 1926/4885CA1 383/4885 |
| US-20180126012-A1 | Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies | CD274, CD47, PDCD1 | FOLH1 2412/4885LTA4H 3388/4885CA1 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.